Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
SANUWAVE Health, Inc. director Tyler James reported receiving a stock option grant. On December 31, 2025, he was awarded 1,540 stock options giving the right to buy common stock at an exercise price of $29.84 per share. These options are shown as fully vested at the grant date and expire on December 31, 2030. After this grant, James beneficially owned 1,540 derivative securities, all held directly.
SANUWAVE Health, Inc. reported an insider equity award for director Jeffrey Blizard. On 12/31/2025, he received a stock option to purchase 1,540 shares of common stock at an exercise price of $29.84 per share, expiring on 12/31/2030.
The option was fully vested on the grant date, meaning it was immediately exercisable. Following this award, Blizard beneficially owns 1,540 derivative securities related to the company’s common stock, held as a direct ownership position.
SANUWAVE Health affiliated holders reported sales of the company’s common stock by a group including JEB Partners, L.P. and related investment entities. On December 11, 2025, they sold 13,500 shares at a weighted average price of $31.2798, followed by a sale of 6,500 shares on December 12, 2025 at a weighted average price of $21.0444, both reported with transaction code “S.”
Following these transactions, 63,999 shares of SANUWAVE Health common stock were reported as indirectly beneficially owned through JEB Partners, L.P., with indirect interests attributed to Manchester Management Company, LLC, Manchester Management PR, LLC and James E. Besser. Additional lines report 2,000 shares directly owned by James E. Besser, 863,980 shares owned directly by Manchester Explorer, L.P., and 52,653 securities and warrants directly owned by Morgan C. Frank, with each party disclaiming beneficial ownership beyond their pecuniary interest.
Sanuwave Health (SNWV) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025.
The company also scheduled a business update conference call for November 7, 2025 at 8:30 a.m. EST. The press release is included as Exhibit 99.1, with materials available on the investor relations website. The information under Item 2.02 is being furnished, not filed.
SANUWAVE Health (SNWV) reported Q3 2025 results with revenue of $11.5M (up 22% year over year) and gross margin of 78%. Operating income was $1.5M. Net income reached $10.3M, driven by a $6.1M favorable change in warrant fair value and $5.0M other income from a patent sale.
Year to date, revenue was $31.0M (up 39%) and operating income was $4.3M. Consumables and parts contributed $7.0M in the quarter; system revenue was $4.4M. Stock‑based compensation totaled $1.4M in Q3.
Balance sheet and liquidity: SANUWAVE closed a new credit agreement with a $23.0M secured term loan (maturing 2029) and a $5.0M revolver (undrawn availability $4.3M as of Sept 30, 2025), and repaid prior senior secured debt. Management states that refinancing and positive operating income alleviated prior going‑concern doubt. Cash was $9.6M; total liabilities were $38.5M. Shares outstanding were 8,576,164 as of Nov 3, 2025.
SANUWAVE Health (SNWV) reported a leadership change and severance terms. Former President Andrew Walko was terminated without cause effective October 24, 2025, and entered a Separation and Release Agreement. The agreement provides $76,666.67 in cash, payable in equal installments over a four-month severance period, with an initial payment of one week’s base salary on October 31, 2025. Walko’s employee stock options will continue to vest during the severance period and remain exercisable until their stated expiration dates. The agreement includes a release of claims, confidentiality, and non-disparagement provisions.
Opaleye Management Inc. reported acquiring 1,267 shares of SANUWAVE Health, Inc. (SNWV) on 10/06/2025 at a weighted average price of $30.277 per share. After the transaction, Opaleye reports beneficial ownership of 966,267 shares through Opaleye, L.P. and an additional 15,000 shares held in a separately managed account for a total indirect position reported.
The filing clarifies the price is a weighted average from multiple trades between $29.75 and $30.50, and states that Opaleye Management Inc. disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed by James Silverman, President, dated 10/09/2025.
SANUWAVE Health, Inc. (SNWV) Form 3 shows Daniel Coyle, the company's Chief Operating Officer and an officer-director, reporting initial beneficial ownership following grants and vesting events. He directly holds 37 shares of common stock and holds options totaling 25,000 underlying shares: a 20,000-share option granted 10/22/2024 exercisable through 10/22/2034 at an exercise price of $14.2, and a second option where 5,000 of the originally granted 10,000 shares vested after achieving two project-based milestones; the remaining 5,000 remain performance‑contingent. The 20,000-share option vests in 12 quarterly installments over three years starting on the grant date. The Form 3 was signed by an attorney-in-fact on 10/06/2025.
Jeffrey Blizard, a company director of SANUWAVE Health, Inc. (SNWV), reported the acquisition of 1,342 shares of common stock through the exercise of a stock option on 09/30/2025. The option had an exercise price of $37.48 and the underlying shares are exercisable through 09/30/2030. The filing states the options were fully vested at grant date and lists the transaction as a direct ownership change. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Ian D. Miller, a director of SANUWAVE Health, Inc. (SNWV), reported a Form 4 showing the acquisition on 09/30/2025 of 1,510 stock options with an exercise price of $37.48. The options were reported as fully vested at grant and are exercisable beginning 09/30/2025 with an expiration of 09/30/203010/02/2025. The filing lists the reporting person’s address in Eden Prairie, MN and indicates the Form was filed by one reporting person.